Previous Close | 6.34 |
Open | 6.45 |
Bid | 6.15 x 1000 |
Ask | 7.00 x 800 |
Day's Range | 6.32 - 6.75 |
52 Week Range | 1.79 - 11.30 |
Volume | |
Avg. Volume | 181,565 |
Market Cap | 218.192M |
Beta (5Y Monthly) | 0.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.36 |
Earnings Date | Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25.71 |
Subscribe to Yahoo Finance Plus to view Fair Value for RPHM
Anticipation Builds for STRIDE Study Results as R&D Expenses Climb
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. “We are looking forward to sharing topline results of our
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences. Jefferies London Healthcare Conference Date: Tuesday, November 14 – Thursday, November 16, 2023 Location: The Waldorf Hilton, London, UK Piper